Switzerland's Clariant Q3 sales beat on higher prices, EBITDA misses on cost pressure
Overview
Switzerland specialty chemical firm's Q3 sales rose 5.6% in local currency, beating analyst expectations
Q3 adjusted EBITDA missed analyst expectations as margins fell on cost phasing and mix effects
Company maintained 2026 guidance, citing strong order book and cost-saving progress
Outlook
Clariant maintains 2026 guidance, expecting sales in local currency to be around flat
Company expects 2026 EBITDA margin before exceptional items of around 18%
Clariant expects free cash flow conversion above 45% in 2026
Result Drivers
PRICING GAINS - Co said sales growth was driven by higher prices across all business units in response to inflationary raw material, energy and logistics costs
MIDDLE EAST IMPACT - Co said Catalysts volumes were negatively affected by the ongoing conflict in the Middle East, leading customers to delay orders
MIX AND COST EFFECTS - Co said margin decline was due to less favorable mix and volatile raw materials affecting costs and inventory valuation in Care Chemicals and Catalysts
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | CHF 968.8 mln | CHF 925.14 mln (7 Analysts) |
Q3 Adjusted EBITDA | Miss | CHF 151.5 mln | CHF 161.20 mln (5 Analysts) |
Q3 EBITDA | CHF 144 mln | ||
Q3 EBITDA Margin | 14.9% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy"
Wall Street's median 12-month price target for Clariant AG is CHF10.75, about 3% above its November 2 closing price of CHF10.44
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
Nov 2 - Chemours Q3 adjusted profit misses estimates despite titanium pricing gains
Nov 2 - Huntsman Q3 revenue beats estimates on higher sales volumes
Nov 3 - Evonik Q3 core profit misses estimates, sees earnings at upper end of guidance
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)